Haemophilus influenzae type b polyribosylribitol phosphate conjugated to carrier protein (Hib-PRP conjugate)

Haemophilus influenzae type b polyribosylribitol phosphate conjugated to carrier protein is a vaccine antigen that consists of the type b capsular polysaccharide (polyribosylribitol phosphate, PRP) from *Haemophilus influenzae* type b chemically linked to a carrier protein, commonly tetanus toxoid. The conjugation transforms the polysaccharide antigen into a T cell-dependent antigen, greatly improving immunogenicity in infants and young children. The PRP is a linear copolymer of ribose and ribitol joined by phosphate diester linkages[1][3], and the conjugated complex induces high-affinity, protective antibodies that prevent invasive Hib disease. This molecular construct defines the target for vaccine-induced immune responses, not as a drug receptor but as an antigenic component used for prophylactic therapy in children and other populations at risk[1][3].

Other names

Hib conjugate vaccinePRP-TT (Polyribosylribitol phosphate conjugated to tetanus toxoid)Hib-PRPHaemophilus influenzae type b polysaccharide conjugate

Induces humoral immune response, especially IgG antibodies against the PRP capsule, conferring protection against *Haemophilus influenzae* type b infection[3].